Microwave ablation: state-of-the-art review

José Irving Hernández
Mario Francisco Jesús Cepeda
Francisco Valdés
Geshel David Guerrero
Instituto Tecnológico de la Laguna, Torreón, Mexico

Abstract: This paper reviews state-of-the-art microwave ablation (MWA) of tumors. MWA is a novel method for treating inoperable tumors, ie, tumors that cannot be treated surgically. However, patients generally choose removal of the tumor by conventional techniques. A literature review of MWA for breast, liver, lung, and kidney tumors is reported here, with tabulation of our findings according to the type of technique used, with a detailed description of the time, type of microwave generator used, and number of patients treated with MWA. In some cases, the subjects were not human patients, but pig or bovine liver specimens. MWA is a technique that has proved to be promising and likely to be used increasingly in the ablation of cancerous tumors. However, MWA needs to be used more widely to establish itself as a common tool in the treatment of inoperable tumors.

Keywords: tumor, ablation, microwave, review

Introduction

A tumor is a swelling of a part of the body, generally without inflammation, caused by an abnormal growth of tissue, whether benign or malignant. Tumors can be cancerous (malignant) or non-cancerous (benign), and occur when cells multiply excessively in the body. Normally, the division and growth of cells occurs in a controlled manner. New cells are created all the time to replace old ones or to perform new functions. Cells that are damaged or are no longer needed die off and are replaced with fresh cells. If the balance of division and cell death is altered, a tumor may appear.

According to 2012 World Health Organization statistics, the most frequent types of cancer worldwide (ranked according to number of deaths globally) are of the lung, prostate, colon, rectum, stomach, and liver (in men), and breast, colon, rectum, lung, cervix, and stomach (in women). There are several methods available to treat cancerous tumors, the most common being surgery, radiotherapy, and systemic chemotherapy. With early detection of tumors, it is possible to use a minimally invasive new technique that works by increasing the temperature inside the tumor hyperthermia, while avoiding damage to healthy adjacent tissue.

Tumor ablation

Placement of a needle or catheter directly into a tumor and the use of heat, cold, or a chemical to destroy it is known as ablation. It is used most frequently to stop the spread of cancer to the bones or liver, although it can also be used in other organs. Ablation is usually employed when only a limited number of tumors are causing problems.

A common type of ablation, ie, radiofrequency ablation, uses a needle that carries an electric current. The end of the needle is placed into the tumor. Ultrasound or computed tomography can be used to ensure that the needle is correctly positioned. An electrical...
current is then passed through the needle, heating the tumor and destroying it. In general, radiofrequency ablation is done while the patient is under general anesthesia. Another type of ablation, known as cryoablation, uses a probe placed inside the tumor to freeze it, which destroys cancer cells. Other methods use heat (laser-induced interstitial thermotherapy) or alcohol to destroy cells.

Microwave tumor ablation

Microwaves are being used increasingly in medicine for ablation of tumors, causing them to be burned and destroyed. Several prototype antennae have been used to perform microwave ablation (MWA). These antennae are designed to be as small as possible and with increasingly precise targeting power to prevent damage to healthy tissue.

<p>| Table 1 Ablation of pig and bovine liver and lung tumors |</p>
<table>
<thead>
<tr>
<th>Microwave generator</th>
<th>Antenna</th>
<th>Time</th>
<th>Patients/tumors</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>2,450 MHz 70–100 W</td>
<td>Microsulis Americas Inc, Waltham, MA, USA, 5.7 mm diameter</td>
<td>4 minutes</td>
<td>Pig liver</td>
<td>Good in liver tissue. The ablation diameters were 3–6.45 cm.</td>
</tr>
<tr>
<td>915 MHz 50–80 W</td>
<td>1.9 mm diameter antenna</td>
<td>10 minutes</td>
<td>Bovine liver</td>
<td>Two antennas were used to achieve a larger and more spherical zone of ablation and coagulation. More desirable coagulation geometry could be obtained by simultaneous application of double antennae at 70 W.</td>
</tr>
<tr>
<td>2,450 MHz 60 or 80 W</td>
<td>14 gauge antenna</td>
<td>10 minutes</td>
<td>8 pig livers</td>
<td>Effective control of the ablation zone was achieved.</td>
</tr>
<tr>
<td>2,450 MHz 60 W</td>
<td>14 gauge antenna</td>
<td>10 minutes</td>
<td>15 pigs with 56 tumors</td>
<td>Three different antenna arrays were compared. The three-antenna array was connected to the death of two pigs.</td>
</tr>
</tbody>
</table>

<p>| Table 2 Ablation of liver tumors in patients |</p>
<table>
<thead>
<tr>
<th>Microwave generator</th>
<th>Antenna</th>
<th>Time</th>
<th>Patients/tumors</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>915 MHz 40 W</td>
<td>3.7 cm of effective radiation</td>
<td>10 minutes</td>
<td>6 patients with 16 liver metastases</td>
<td>They require improvements before MWA can be used on a routine basis.</td>
</tr>
<tr>
<td>2,450 MHz 20–80 W</td>
<td>14 gauge, Amica-Gen, HS Hospital Service SpA, Aprilia, Italy</td>
<td>8–10 minutes</td>
<td>6 patients</td>
<td>5 patients showed disease-free survival.</td>
</tr>
<tr>
<td>915 MHz, 2,450 MHz</td>
<td>1–3 13 gauge antennae</td>
<td>9.7 minutes with 915 MHz, 6.6 minutes with 2,450 MHz</td>
<td>48 patients with 124 tumors, 72 with 915 MHz, 52 with 2,450 MHz</td>
<td>Both systems manage ablation of liver tumors but the 2,450 MHz system achieves more rapid and predictable ablations.</td>
</tr>
<tr>
<td>2,450 MHz 100 W</td>
<td>5 mm antenna</td>
<td>4 minutes</td>
<td>140 patients in 18 hospitals with 299 tumors</td>
<td>Morbidity was 8.3% and in-hospital mortality was 1.9%.</td>
</tr>
<tr>
<td>902–928 MHz 10–32 W</td>
<td>14 gauge antenna</td>
<td>10 minutes</td>
<td>10 tumors in 10 patients (5 male, 5 female)</td>
<td>6 of &lt;3 cm tumors showed complete necrosis and the rest had 50% partial necrosis.</td>
</tr>
<tr>
<td>2,450 MHz 60–100 W</td>
<td>14 or 16 gauge antenna</td>
<td>5–15 minutes</td>
<td>736 patients with 1,037 tumors in 14 hospitals</td>
<td>22 major complications and 54 minor complications were observed, with no mortality.</td>
</tr>
<tr>
<td>915 MHz 45 W</td>
<td>Not specified</td>
<td>10 minutes</td>
<td>87 patients with 224 tumors</td>
<td>The mortality rate was 2.3%, local recurrence occurred in 6 tumors and regional recurrence occurred in 37 tumors.</td>
</tr>
<tr>
<td>915 MHz and 2,450 MHz</td>
<td>14.5 gauge antenna for the 915 MHz generator and 14 gauge antenna for the 2,450 MHz generator</td>
<td>10 minutes</td>
<td>15 patients with 19 inoperable tumors</td>
<td>100% success, with only 2 cases of complications at 8 months of follow-up. A 915 MHz generator was used in 11 patients and 2,450 MHz in the remaining 4.</td>
</tr>
</tbody>
</table>

Abbreviation: MWA, microwave ablation.
Table 3 Ablation of lung tumors in patients

<table>
<thead>
<tr>
<th>Microwave generator</th>
<th>Antenna</th>
<th>Time</th>
<th>Patients/tumors</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>915 MHz 45 W</td>
<td>14.5 gauge antenna</td>
<td>10 minutes</td>
<td>24 patients with 26 inoperable tumors</td>
<td>Technical success in 100%, without major complications. 1, 3, and 6 months and annually follow, was observed complete necrosis in 61.6% of lesions. Partial necrosis in 30.8% and progression of disease in only one case.</td>
</tr>
<tr>
<td>2,450 MHz 120 W or 180 W</td>
<td>1.8 mm diameter antenna</td>
<td>2 minutes in &lt;2 cm tumors, 3.5 minutes in 2–3 cm tumors, 4–6 minutes in 3–5 cm tumors</td>
<td>120 W: 1 minute for 1 cm tumors, 8 minutes for 2.4 cm tumors</td>
<td>23 patients with 29 tumors</td>
</tr>
<tr>
<td>902–928 MHz 10–32 W</td>
<td>14 gauge antenna</td>
<td>10 minutes</td>
<td>10 patients</td>
<td>5 of 10 specimens were clearly measurable with a maximum diameter of ablation of 4.8 cm and volume of zone of ablation was on average 15.1 cm.</td>
</tr>
</tbody>
</table>

Abbreviation: MvA, microwave ablation.

The expectations generated by MWA have also sparked other investigations. Researchers are developing such antennae to generate heat via microwaves, as shown in figure 1, and more patents are being granted for different antenna designs. The development of new software tools and other advances have led to the appearance of new methods for application of microwaves to ablate tumors. The figure 2 show the simulation of Microwave applicator inserted in breast tissue. Many research groups are investigating the effectiveness of MWA in the treatment of cancer. As they progress, there are more studies published on the evaluation, the comparison to other techniques and the application of ablation using microwaves. The tables included in this paper show the main features of some of the studies published in recent years.

Table 1 shows that MWA offers a good ablation zone of approximately 3–4 cm (in one experiment, the ablation zone was 6.45 cm). In the last study mentioned in this table, the applicator was an array of three antennae, and the paper concludes that a single antenna can ablate tumors less than 4 cm in length and avoid damage to the lung.

The tables that follow show the results using different applicators to treat tumors in human patients. Many researchers have used the liver to test MWA because it is an organ that is difficult to operate on, and therefore alternative treatments, such as MWA, are appealing. Table 2 shows that MWA is an effective alternative treatment, with outcomes similar to those of surgery. The difference between the test frequencies was the therapy time; a frequency of 2,450 MHz allows more ablation than others. In further clinical trials conducted

Table 4 Ablation of kidney tumors in patients

<table>
<thead>
<tr>
<th>Microwave generator</th>
<th>Antenna</th>
<th>Time</th>
<th>Patients/tumors</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>915 MHz 45 W</td>
<td>14.5 gauge antenna</td>
<td>10 minutes</td>
<td>12 patients</td>
<td>Patients had a 3–14-month follow-up to observe the therapeutic effects and complications. There were no serious complications or unexpected side effects after ablation.</td>
</tr>
<tr>
<td>2,450 MHz 50 W</td>
<td>15 gauge antenna coated with ethylene polytetrafluoride</td>
<td>8 minutes</td>
<td>48 patients with MWA, 54 patients with partial nephrectomy</td>
<td>3-year survival was 91.3% for MWA and 96% for partial nephrectomy.</td>
</tr>
</tbody>
</table>

Abbreviation: MvA, microwave ablation.
in 60 patients with 96 tumors measuring 1–8 cm, complete ablation was observed in 89 tumors.\(^7\)

The conclusion of Tables 3 and 4 is similar to that for liver tumors, ie, MWA is a viable treatment option for lung and kidney tumors, with results similar to those of surgery when patients are followed up at 1, 3, and 6 months for lung and kidney tumors, and complete necrosis were seen in most patients.

There are presently no data available on the use of MWA in breast cancer. However, in 2011, Cepeda suggested using MWA for this type of cancer. Figure 3 shows the injury caused by the applicator, which was used in the ex vivo test. In his doctoral thesis, he elaborated the design of an applicator for minimally invasive MWA, performing a computational analysis by finite element modeling, and then validated the model with experiments on phantoms and ex vivo porcine tissue breast.\(^49\)

**Conclusion**

MWA has proven to be a successful therapeutic tool in the treatment of cancer. Its use is expected to increase in frequency for ablation of tumors. Although many successful tests have been done, MWA has not progressed to widespread use in dedicated cancer treatment centers, in particular for inoperable tumors (even though most of the clinical studies have been done in people who could not be treated by surgery). The advantages of MWA need to be recognized more widely, given that it has been proven to be effective. Hospitals should consider acquiring the expertise and infrastructure needed to establish MWA for the treatment of cancers, and thus offer patients an alternative treatment option.

**Disclosure**

The authors report no conflicts of interest in this work.
References


